Guerbet
Medical Imaging Systems · APIs & Drug Manufacturing
Overview
Guerbet is a French pharmaceutical company specialising in contrast agents and related injection systems and solutions for medical imaging. It operates in many countries, including a US site in Cincinnati that hires software engineers for medical devices. The company is headquartered in Villepinte, France.
Growth
Hiring Momentum
35/100
Slowing
Open positions
0
0 opened / 0 closed in 30 days
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Backend
100% ▲
Financials
Est. Annual Revenue
$849.4M
2025
Total raised
$648k
Latest round
Grant
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Grant | 2025 | $648k | Details |
People
Philippe Bourrinet
Directeur général délégué
Karim Boussebaa
Directeur Général
Antoine Fady
Président du conseil d’administration
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
News
Guerbet : H1 2026 Results.
H1 2026 ResultsRevenue of €379.2m, nearly stable (-0.1%) at CER1 and like-for-like2, in line with the Group's forecast for the full yearEBITDA of ...
Read more
Report
Report
New indication in children from birth for Guerbet
/PRNewswire/ -- Guerbet (FR0000032526 GBT), a global specialist in contrast media and solutions for medical imaging, is delighted to announce the approval by...
Read more
Report
GUERBET : Mise à disposition du Document d'enregistrement universel 2023 - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Guerbet: Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Guerbet: 2023 Strategic Priorities - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Guerbet to Spotlight the Novel New Drug Elucirem (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting
/PRNewswire/ -- Guerbet LLC, the US affiliate of Guerbet, a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical...
Read more
Report
Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects
Guerbet announces a change in governance for its Artificial Intelligence projects Villepinte, November 3rd, 2022: Guerbet today announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018. Guerbet today ann
Read more
Report
Guerbet makes the CDP A grade for its commitment to the fight against global warming
Guerbet makes the CDP A grade1 for its commitment to the fight against global warming This award places Guerbet in the CDP leadership group for its environmental commitment and performance as part of its corporate strategy. Villepinte (France), 17 Decembe
Read more
Report
Guerbet announces the acquisition of a new microsphere technology to strengthen its interventional imaging range
Acquisition of a technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization; This new technology will round out Guerbets Interventional Imaging ...
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Villepinte
France
HQ
Earlier presence
Cincinnati, United States